HomeAI · summaries
Storia in 7 fonti
Updated: Novartis sinks after second disastrous trial failure, this time of Avidity-acquired drug
Novartis' del-desiran misses HARBOR trial's primary endpoint, adding to pelacarsen miss and CAR-T deaths; shares sink 10%.
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
endpoints.news
Novartis' Phase 3 cardiovascular study miss raises the stakes for Amgen, Lilly
Novartis' pelacarsen fails Lp(a)HORIZON, the third major CV outcomes trial miss in two months, as Amgen, Lilly and others push ahead.
- ·
biopharmadive.com
Novartis RNA drug falls short in rare muscle disease study
The failure of “del-desiran,” which Novartis got through a $12 billion acquisition, could raise questions about the company’s business development acumen, according to one analyst.
